[go: up one dir, main page]

CL2009002036A1 - Use of a composition comprising 100% by weight of trans-clomiphene, as an active ingredient, salts or solvates thereof to prepare a medicament useful for preventing or treating type 2 diabetes mellitus in a male subject. - Google Patents

Use of a composition comprising 100% by weight of trans-clomiphene, as an active ingredient, salts or solvates thereof to prepare a medicament useful for preventing or treating type 2 diabetes mellitus in a male subject.

Info

Publication number
CL2009002036A1
CL2009002036A1 CL2009002036A CL2009002036A CL2009002036A1 CL 2009002036 A1 CL2009002036 A1 CL 2009002036A1 CL 2009002036 A CL2009002036 A CL 2009002036A CL 2009002036 A CL2009002036 A CL 2009002036A CL 2009002036 A1 CL2009002036 A1 CL 2009002036A1
Authority
CL
Chile
Prior art keywords
clomiphene
preventing
composition
diabetes mellitus
trans
Prior art date
Application number
CL2009002036A
Other languages
Spanish (es)
Inventor
Fremont Inc Amgen
Products Inc Pfizer
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009002036(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of CL2009002036A1 publication Critical patent/CL2009002036A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método para prevenir o tratar la diabetes mellitus tipo 2 que comprende administrar una composición que comprende un antiestrógeno, escencialmente trans-clomifeno, que incrementa la sensibilidad a insulina y reduce los niveles de glucosa en ayuno, la concentración de glucosa en el suero y la concentración serica de triglicéridos.Method for preventing or treating type 2 diabetes mellitus comprising administering a composition comprising an antiestrogen, essentially trans-clomiphene, which increases insulin sensitivity and reduces fasting glucose levels, serum glucose concentration and concentration triglyceride serum.

CL2009002036A 2008-11-07 2009-11-05 Use of a composition comprising 100% by weight of trans-clomiphene, as an active ingredient, salts or solvates thereof to prepare a medicament useful for preventing or treating type 2 diabetes mellitus in a male subject. CL2009002036A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11245808P 2008-11-07 2008-11-07

Publications (1)

Publication Number Publication Date
CL2009002036A1 true CL2009002036A1 (en) 2010-02-05

Family

ID=41404260

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009002036A CL2009002036A1 (en) 2008-11-07 2009-11-05 Use of a composition comprising 100% by weight of trans-clomiphene, as an active ingredient, salts or solvates thereof to prepare a medicament useful for preventing or treating type 2 diabetes mellitus in a male subject.

Country Status (4)

Country Link
AR (1) AR074302A1 (en)
CL (1) CL2009002036A1 (en)
TW (2) TW201500041A (en)
WO (1) WO2010054248A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1411916T3 (en) 2001-07-09 2008-12-15 Repros Therapeutics Inc Methods and Materials for Treating Testosterone Deficiency in Men
UA113291C2 (en) 2011-08-04 2017-01-10 TRANSCLOMYPHENE METABOLITES AND THEIR APPLICATIONS
AU2013221478B2 (en) * 2012-02-14 2017-06-01 Repros Therapeutics Inc. Selective estrogen receptor modulators with short half-lives and uses thereof
CA2880388A1 (en) * 2012-08-21 2014-02-27 Repros Therapeutics Inc. Trans-clomiphene formulations and uses thereof
HK1216502A1 (en) * 2012-11-02 2016-11-18 Repros Therapeutics Inc. Trans-clomiphene for cancer treatment
CN108883083A (en) * 2016-02-25 2018-11-23 艾森潘帕克制药股份有限公司 The peroral dosage form of two kinds of Clomifene isomers and the method for treating secondary hypogonadism using it
CA2989364C (en) 2016-04-22 2021-07-20 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for the preparation of enclomiphene citrate having needle shaped crystal habit.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
JP5785680B2 (en) * 2005-03-22 2015-09-30 リプロス セラピューティクス インコーポレイテッド Dosing regimen for trans-clomiphene
EP1829534A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
CN102940619A (en) * 2007-10-16 2013-02-27 利普生物药剂公司 Trans-clomiphene for metabolic syndrome

Also Published As

Publication number Publication date
WO2010054248A1 (en) 2010-05-14
TW201500041A (en) 2015-01-01
TWI458478B (en) 2014-11-01
AR074302A1 (en) 2011-01-05
TW201031400A (en) 2010-09-01

Similar Documents

Publication Publication Date Title
CL2009002036A1 (en) Use of a composition comprising 100% by weight of trans-clomiphene, as an active ingredient, salts or solvates thereof to prepare a medicament useful for preventing or treating type 2 diabetes mellitus in a male subject.
CL2009001340A1 (en) Composed of pegylated insulin lispro or a salt thereof comprising a chain a of sec no: 1, a chain b of sec no: 3 and the peg is of a weight between 20 to 40 kda; use of said compound to treat hypoglycemia or diabetes; pharmaceutical composition comprising said compound; and process for making said compound.
MX2016015669A (en) Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist.
AR081254A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AVE0010 AND INSULIN GLARGINE
CL2008001612A1 (en) 5- (3-hydroxy-7-substituted-naphthalen-2-yl) -1, 1-dioxo- [1,2,5] thiadiazolidin-3-one; its use to treat a hyperproliferative disorder; the pharmaceutical composition that contains them; and its preparation processes.
CL2013000716A1 (en) A prodrug or a salt thereof comprising an exendin-conjugate conjugate; preparation procedure of said prodrug; intermediary compounds; pharmaceutical composition that includes it, useful to improve glycemic control in patients with type 2 diabetes.
CL2013001104A1 (en) Pharmaceutical composition comprising a sglt2 inhibitor and an insulin; and use to treat a disease or condition such as diabetes mellitus, diabetes mellitus type 1 and 2, among others.
CL2012001337A1 (en) Use of a pharmaceutical combination comprising a dpp-4 inhibitor and optionally a second and / or a third diabetic agent selected from biguanides, thiazolidinediones, sulfonylureas, glinides, alpha-glucosidase inhibitors, glp-1 and insulin, different from one another, for the treatment of type 2 diabetes mellitus.
ECSP10010106A (en) TRANS-CLOMPHENE FOR METABOLIC SYNDROME
AR081200A1 (en) INSULIN FORMULATIONS OF PROLONGED ACTION
CY1119582T1 (en) HYDRAULIC INSULIN PREPARATIONS CONTAINING Methionine
CO6361944A2 (en) COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
PE20120018A1 (en) PHARMACEUTICAL COMPOSITION OF LINAGLIPTIN AND 1-CHLORINE-4- (B-D-GLUCOPYRANES-1-IL) -2- [4 - ((S) -TETRAHYDROFURAN-3-ILOXI) -BENZYL] -BENZENE, PHARMACEUTICAL FORM AND PROCEDURE FOR ITS PREPARATION
GT201400136A (en) COMPOUNDS AND METHODS OF BENZALDEHYDE SUBSTITUTED FOR USE IN INCREASING OXYGENATION OF FABRICS
CL2011000899A1 (en) Aryl compounds, modulators of gpr120 activity in a cell; pharmaceutical composition; and use of said compounds for the treatment of type i, ii diabetes, metabolic syndrome, stimulate insulin production, lower blood glucose level.
UY31596A1 (en) NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / ACTION PROFILE
CL2010001526A1 (en) Compounds derived from isonicotinamide, modulators of stearoyl-coa-desaturase; Pharmaceutical composition comprising a compound; useful for treating diseases related to dyslipidemia and disorders of lipid metabolism.
CO6541566A2 (en) PHARMACEUTICAL COMPOSITION INCLUDING A GLP -1 AND METIONINE AGONIST
CL2009000173A1 (en) Compounds derived from urea-tetrahydroxyquinoxaline; preparation procedure; intermediate compounds; pharmaceutical composition; and use for the treatment and prevention of obesity and diabetes, insulin resistance, metabolic syndrome, among others.
CL2012001232A1 (en) Liquid pharmaceutical composition comprising a glp-1 agonist: despro36 exendin-4- (1-39) -lys6-nh2, human insulin gly (a21) -arg (b31) -arg (b32), or salts thereof, l -methionine and optionally an excipient; combination; kit; Preparation method; use to treat diabetes.
CL2012000469A1 (en) Pharmaceutical composition comprising a slowly absorbing insulin conjugate compound; a container; a suspension comprising the composition and its method of preparation; its use for the treatment or prevention of a pathology associated with insulin deficiency, such as diabetes; a kit.
CL2011001927A1 (en) Use of a sustained release pharmaceutical composition, comprising as active ingredient 4-aminopyridine, which is used to prepare a useful medication for the treatment of multiple sclerosis, in two doses of 10 milligrams daily, which allows the recovery of a patient's gait affected.
CO6640324A2 (en) Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
CL2012000797A1 (en) Compounds derived from pyrazole, modulators of stearoyl-coa-desaturase; pharmaceutical composition comprising them; and its use for the treatment of a disease or condition such as metabolic syndrome, diabetes, insulin resistance, diabetic complications, and body weight disorders.
CL2014001705A1 (en) Compounds derived from aza adamantane, 11beta-hsd-1 inhibitors; pharmaceutical composition; method for prevention or treatment; and use to prevent or treat metabolic syndrome, type 2 diabetes as a result of obesity, insulin resistance, dyslipidemia, neuropathy, ischemia and infarction, among other diseases.